title: Fentanyl for breakthrough cancer pain--what's new?
authors.affiliation: Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku and Turku University Hospital, P.O. Box 52, FI-20521 Turku, Finland.
authors.forename: Nora M
authors.initials: NM
authors.lastname: Hagelberg
authors.forename: Klaus T
authors.initials: KT
authors.lastname: Olkkola
mesh_terms: D000701:Analgesics, Opioid / Q000627:therapeutic use; D005283:Fentanyl / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000701:Analgesics, Opioid; D005283:Fentanyl
references.citation: Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulphate immediate release (MSIR®). Pain. 2001;91:123-130.
references.citation: Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability od fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, cross-over study. Clin Ther. 2008;30:469-481.
references.citation: Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate (OTFC): Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-616.
references.citation: Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev. 2006;58:1076-1088.
references.citation: Jekunen AP, Cotterill-Jones C, Dewlan P, Tanner T, Sikorska H, Asking L, Jouhikainen T. Dose linearity of inhaled fentanyl with comparative pharmacokinetics to transmucosal fentanyl. J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I). 2006;24:8629.
references.citation: Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics. Focus on methodology. Clin J Pain. 2009;25:797-807.
references.citation: Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177-1191.
references.citation: Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: and open-label, randomised, crossover trial. Curr Med Opin Res. 2009;25:2805-2815.
references.citation: Moksnes K, Fredheim OM, Klepstad P, Kaasa S, Angelsen A, Nilsen T, Dale O. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol. 2008;64:497-502.
references.citation: Portenoy R, Burton AW, Gabrail N, Taylor D, on behalf of the fentanyl Pectin Nasal Spray 043 group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151:617–24.
references.citation: Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
references.citation: Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-811.